Company intelligence / Profile preview

Cantab Anti-Infectives

London, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Cantab Anti-Infectives had an active preclinical antibacterial pipeline focused on peptide-derived antibiotics for multidrug resistant Gram-negative infections, with lead optimization ongoing circa 2014. Their lead program targeted improvements in efficacy and safety of polymyxin-based therapies. No clinical results or advanced-stage data are available; company appears closed/changed name in 2019[1][2][4].

Therapeutic areas: Infectious Diseases
Modalities: PeptidesSmall molecule
Industry: Biotech

Partnerships

Euprotec LimitedSelcia Limited

Beyond the preview

Go deeper on Cantab Anti-Infectives.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cantab Anti-Infectives.

Explore the full profile